Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	intracellularly gated calcium channel activity	TPCN2 RYR1 ITPR2	7.11e-05	18	91	3	GO:0015278
GeneOntologyMolecularFunction	low-affinity IgG receptor activity	FCGR3A FCGR3B	1.23e-04	4	91	2	GO:0019772
GeneOntologyMolecularFunction	IgE receptor activity	FCGR3A FCGR3B	3.04e-04	6	91	2	GO:0019767
GeneOntologyMolecularFunction	ligand-gated calcium channel activity	TPCN2 RYR1 ITPR2	3.75e-04	31	91	3	GO:0099604
GeneOntologyMolecularFunction	IgE binding	FCGR3A FCGR3B	4.25e-04	7	91	2	GO:0019863
GeneOntologyMolecularFunction	IgG receptor activity	FCGR3A FCGR3B	4.25e-04	7	91	2	GO:0019770
GeneOntologyMolecularFunction	intracellularly ligand-gated monoatomic ion channel activity	TPCN2 RYR1 ITPR2	4.52e-04	33	91	3	GO:0005217
GeneOntologyBiologicalProcess	protein-containing complex localization	RELN NRXN3 FCGR3A FCGR3B ATM SNAP25 TERF1 TSPAN9 PCM1	3.51e-06	278	90	9	GO:0031503
GeneOntologyBiologicalProcess	perforin production	FCGR3A FCGR3B	1.88e-05	2	90	2	GO:0035944
GeneOntologyBiologicalProcess	antibody-dependent cellular cytotoxicity	FCGR3A FCGR3B IGHG4	2.23e-05	13	90	3	GO:0001788
GeneOntologyBiologicalProcess	negative regulation of telomere maintenance	PARP1 ATM TERF1 SMG6	3.34e-05	42	90	4	GO:0032205
GeneOntologyBiologicalProcess	type IIa hypersensitivity	FCGR3A FCGR3B IGHG4	3.52e-05	15	90	3	GO:0001794
GeneOntologyBiologicalProcess	type II hypersensitivity	FCGR3A FCGR3B IGHG4	3.52e-05	15	90	3	GO:0002445
GeneOntologyBiologicalProcess	embryo development	HINFP LATS1 KIDINS220 FOXL2 KIAA1217 TTLL4 KIF1B ENAH LAMA2 TSHZ1 CHD7 MSH2 ATM ECE1 THOC2 KIT YTHDF2 XAB2	4.12e-05	1437	90	18	GO:0009790
GeneOntologyBiologicalProcess	establishment of RNA localization to telomere	ATM TERF1	5.63e-05	3	90	2	GO:0097694
GeneOntologyBiologicalProcess	establishment of protein-containing complex localization to telomere	ATM TERF1	5.63e-05	3	90	2	GO:0097695
GeneOntologyBiologicalProcess	negative regulation of DNA metabolic process	PARP1 ENPP7 MSH2 ATM TERF1 SMG6	6.05e-05	155	90	6	GO:0051053
GeneOntologyBiologicalProcess	hypersensitivity	FCGR3A FCGR3B IGHG4	1.72e-04	25	90	3	GO:0002524
GeneOntologyBiologicalProcess	embryo development ending in birth or egg hatching	HINFP LATS1 KIDINS220 KIAA1217 TTLL4 KIF1B ENAH CHD7 MSH2 ATM ECE1 THOC2 XAB2	1.90e-04	929	90	13	GO:0009792
GeneOntologyBiologicalProcess	regulation of telomere maintenance via telomere lengthening	PARP1 ATM TERF1 SMG6	2.36e-04	69	90	4	GO:1904356
GeneOntologyBiologicalProcess	positive regulation of bone resorption	FCGR3A FCGR3B CA2	2.43e-04	28	90	3	GO:0045780
GeneOntologyCellularComponent	chromosome, telomeric region	PARP1 POLR2B MSH2 ATM THOC2 TERF1 SMG6	1.10e-05	176	90	7	GO:0000781
GeneOntologyCellularComponent	Fc-gamma receptor III complex	FCGR3A FCGR3B	1.09e-04	4	90	2	GO:0033001
Domain	PRT_C	MCTP1 MCTP2	2.19e-05	2	88	2	PF08372
Domain	PRibTrfase_C	MCTP1 MCTP2	2.19e-05	2	88	2	IPR013583
Domain	YTH	YTHDF1 YTHDF2	2.17e-04	5	88	2	PF04146
Domain	YTH_domain	YTHDF1 YTHDF2	2.17e-04	5	88	2	IPR007275
Domain	YTH	YTHDF1 YTHDF2	2.17e-04	5	88	2	PS50882
Domain	RIH_assoc-dom	RYR1 ITPR2	3.25e-04	6	88	2	IPR013662
Domain	Ins145_P3_rec	RYR1 ITPR2	3.25e-04	6	88	2	PF08709
Domain	RIH_assoc	RYR1 ITPR2	3.25e-04	6	88	2	PF08454
Domain	RIH_dom	RYR1 ITPR2	3.25e-04	6	88	2	IPR000699
Domain	Ins145_P3_rcpt	RYR1 ITPR2	3.25e-04	6	88	2	IPR014821
Domain	Ryanodine_recept-rel	RYR1 ITPR2	3.25e-04	6	88	2	IPR015925
Domain	-	RYR1 ITPR2	3.25e-04	6	88	2	1.25.10.30
Domain	RYDR_ITPR	RYR1 ITPR2	3.25e-04	6	88	2	PF01365
Domain	Peptidase_M13_C	ECE1 ECE2	4.54e-04	7	88	2	IPR018497
Domain	Peptidase_M13	ECE1 ECE2	4.54e-04	7	88	2	IPR000718
Domain	Peptidase_M13_N	ECE1 ECE2	4.54e-04	7	88	2	PF05649
Domain	Peptidase_M13_N	ECE1 ECE2	4.54e-04	7	88	2	IPR008753
Domain	Peptidase_M13	ECE1 ECE2	4.54e-04	7	88	2	PF01431
Domain	EF-hand_8	EFCAB6 CAPN3 RYR1	5.44e-04	34	88	3	PF13833
Domain	DNA/RNA_helicase_DEAH_CS	DHX57 CHD7 DHX8	5.93e-04	35	88	3	IPR002464
Domain	DEAH_ATP_HELICASE	DHX57 CHD7 DHX8	7.57e-04	38	88	3	PS00690
Domain	MIR	RYR1 ITPR2	9.64e-04	10	88	2	PF02815
Domain	MIR_motif	RYR1 ITPR2	9.64e-04	10	88	2	IPR016093
Domain	MIR	RYR1 ITPR2	9.64e-04	10	88	2	PS50919
Domain	MIR	RYR1 ITPR2	9.64e-04	10	88	2	SM00472
Domain	EGF_extracell	RELN TNN TENM1	2.85e-03	60	88	3	IPR013111
Domain	EGF_2	RELN TNN TENM1	2.85e-03	60	88	3	PF07974
Domain	DUF1605	DHX57 DHX8	2.85e-03	17	88	2	IPR011709
Domain	OB_NTP_bind	DHX57 DHX8	2.85e-03	17	88	2	PF07717
Domain	HA2	DHX57 DHX8	3.20e-03	18	88	2	SM00847
Domain	HA2	DHX57 DHX8	3.20e-03	18	88	2	PF04408
Domain	Helicase-assoc_dom	DHX57 DHX8	3.20e-03	18	88	2	IPR007502
Domain	Fibrinogen_CS	TNN FGL1	3.56e-03	19	88	2	IPR020837
Domain	PDEase	PDE8A PDE11A	3.56e-03	19	88	2	IPR023088
Domain	PDEase_I	PDE8A PDE11A	4.35e-03	21	88	2	PF00233
Domain	PDEASE_I	PDE8A PDE11A	4.35e-03	21	88	2	PS00126
Domain	PDEase_CS	PDE8A PDE11A	4.35e-03	21	88	2	IPR023174
Domain	-	PDE8A PDE11A	4.77e-03	22	88	2	1.10.1300.10
Domain	TPR-like_helical_dom	EEF2K GPSM1 XAB2 TTC6 SMG6	4.90e-03	233	88	5	IPR011990
Domain	EGF	RELN NRXN3 TNN TENM1 LAMA2	5.08e-03	235	88	5	SM00181
Domain	PDEase_catalytic_dom	PDE8A PDE11A	5.21e-03	23	88	2	IPR002073
Domain	HD/PDEase_dom	PDE8A PDE11A	5.66e-03	24	88	2	IPR003607
Domain	Fibrinogen_a/b/g_C_2	TNN FGL1	5.66e-03	24	88	2	IPR014715
Domain	-	TNN FGL1	5.66e-03	24	88	2	4.10.530.10
Domain	HDc	PDE8A PDE11A	5.66e-03	24	88	2	SM00471
Domain	WGR_domain	PARP1 LAMA2	5.66e-03	24	88	2	IPR008893
Pubmed	MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.	PARP1 FARSA RELN CSE1L KIDINS220 POLR2B SUGP1 DHX57 CHD7 RPL14 EIF3B ATM THOC2 TERF1 XAB2 DHX8	2.37e-08	1082	92	16	38697112
Pubmed	Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.	PARP1 FARSA CSE1L KIAA1217 PKP4 POLR2B ARPC1A OAS3 MSH2 RPL14 EIF3B THOC2 YTHDF2 XAB2 LRRFIP2 DHX8 ITPR2	3.00e-08	1257	92	17	36526897
Pubmed	A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape.	PARP1 FARSA CSE1L POLR2B LTN1 DHX57 OAS3 PCMTD2 MSH2 RPL14 EIF3B ATM SNAP25 THOC2 YTHDF2 PCM1 LRRFIP2 ITPR2	3.68e-08	1440	92	18	30833792
Pubmed	The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis.	YTHDF1 LATS1 PKP4 KIF1B ENAH GPSM1 PCM1 SMG6	1.24e-07	218	92	8	33378226
Pubmed	Telomere-Internal Double-Strand Breaks Are Repaired by Homologous Recombination and PARP1/Lig3-Dependent End-Joining.	PARP1 ATM TERF1	1.78e-07	5	92	3	27806302
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	DNHD1 PARP1 FARSA CSE1L KIDINS220 ANAPC1 POLR2B ARPC1A ENAH MSH2 RPL14 EIF3B ATM THOC2 CA2 LRRFIP2 DHX8	1.80e-07	1425	92	17	30948266
Pubmed	SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.	HINFP PARP1 LTN1 DHX57 EEF2K RPL14 EIF3B DHX8	3.53e-07	250	92	8	33536335
Pubmed	FAM188B enhances cell survival via interaction with USP7.	ANAPC1 POLR2B RPL14 EIF3B PCM1	8.46e-07	65	92	5	29795372
Pubmed	Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.	PARP1 FARSA LATS1 CSE1L PKP4 POLR2B KIF1B MSH2 HMGCS1 RPL14 EIF3B THOC2 MAP2K3 LRRFIP2 DHX8	9.43e-07	1247	92	15	27684187
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	CSE1L ANAPC1 DHX57 CHD7 MSH2 RPL14 ATM THOC2 PCM1 XAB2 DHX8	1.28e-06	653	92	11	22586326
Pubmed	FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo.	FCGR3A FCGR3B IGHG4	1.49e-06	9	92	3	20974962
Pubmed	Cutting Edge: The murine high-affinity IgG receptor FcγRIV is sufficient for autoantibody-induced arthritis.	FCGR3A FCGR3B KIT	2.91e-06	11	92	3	21248252
Pubmed	Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.	YTHDF1 PARP1 FARSA MYH11 CSE1L POLR2B RPL14 EIF3B YTHDF2 XAB2 DHX8	3.01e-06	714	92	11	28302793
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	YTHDF1 PARP1 FARSA MYH11 CSE1L DHX57 OAS3 CHD7 RPL14 PLD1 THOC2 YTHDF2 PCM1 XAB2 LRRFIP2	3.03e-06	1371	92	15	36244648
Pubmed	An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity.	YTHDF1 FARSA ANAPC1 TTLL4 POLR2B SUGP1 CHD7 YTHDF2 PCM1 DHX8 ITPR2	3.87e-06	733	92	11	34672954
Pubmed	MCM8 interacts with DDX5 to promote R-loop resolution.	PARP1 FOXL2 ATM	5.03e-06	13	92	3	38858601
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	PARP1 FARSA MYH11 CSE1L KIDINS220 KIAA1217 PKP4 KIF1B ARPC1A DHX57 RPL14 PCM1 CA2 LRRFIP2 ITPR2	5.08e-06	1431	92	15	37142655
Pubmed	The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis.	FARSA CSE1L POLR2B DHX57 MSH2 RPL14 THOC2 TERF1 YTHDF2 LRRFIP2 DHX8	5.38e-06	759	92	11	35915203
Pubmed	Human Fc gamma RIII: cloning, expression, and identification of the chromosomal locus of two Fc receptors for IgG.	FCGR3A FCGR3B	6.92e-06	2	92	2	2521732
Pubmed	Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents.	PARP1 ATM	6.92e-06	2	92	2	17428792
Pubmed	Single-cell analyses identify dysfunctional CD16+ CD8 T cells in smokers.	FCGR3A FCGR3B	6.92e-06	2	92	2	33163982
Pubmed	Association study of copy number variants in FCGR3A and FCGR3B gene with risk of ankylosing spondylitis in a Chinese population.	FCGR3A FCGR3B	6.92e-06	2	92	2	26494566
Pubmed	Poly(ADP-ribose) polymerase activity is not affected in ataxia telangiectasia cells and knockout mice.	PARP1 ATM	6.92e-06	2	92	2	9934867
Pubmed	Developmental origin and Kit-dependent development of the interstitial cells of cajal in the mammalian small intestine.	MYH11 KIT	6.92e-06	2	92	2	9438424
Pubmed	N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency.	YTHDF1 YTHDF2	6.92e-06	2	92	2	26046440
Pubmed	Impact of allele copy number of polymorphisms in FCGR3A and FCGR3B genes on susceptibility to ulcerative colitis.	FCGR3A FCGR3B	6.92e-06	2	92	2	23917248
Pubmed	Evidence for gene recombination in FCGR3 gene variants.	FCGR3A FCGR3B	6.92e-06	2	92	2	19320901
Pubmed	Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes.	FCGR3A FCGR3B	6.92e-06	2	92	2	25966632
Pubmed	The Fc gamma receptor of natural killer cells is a phospholipid-linked membrane protein.	FCGR3A FCGR3B	6.92e-06	2	92	2	2967436
Pubmed	Etiology of ovarian failure in blepharophimosis ptosis epicanthus inversus syndrome: FOXL2 is a conserved, early-acting gene in vertebrate ovarian development.	FOXL2 KIT	6.92e-06	2	92	2	12810580
Pubmed	Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca2+ binding properties.	MCTP1 MCTP2	6.92e-06	2	92	2	15528213
Pubmed	Poly(ADP-ribose) polymerase-1 inhibits ATM kinase activity in DNA damage response.	PARP1 ATM	6.92e-06	2	92	2	15178448
Pubmed	Low copy numbers of FCGR3A and FCGR3B associated with Chinese patients with SLE and AASV.	FCGR3A FCGR3B	6.92e-06	2	92	2	28355982
Pubmed	The human low affinity immunoglobulin G Fc receptor III-A and III-B genes. Molecular characterization of the promoter regions.	FCGR3A FCGR3B	6.92e-06	2	92	2	7836402
Pubmed	Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.	FCGR3A FCGR3B	6.92e-06	2	92	2	25816339
Pubmed	Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development.	ECE1 ECE2	6.92e-06	2	92	2	10811845
Pubmed	Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.	MSH2 LGR5	6.92e-06	2	92	2	25088490
Pubmed	Multiple C2 domain-containing transmembrane proteins promote lipid droplet biogenesis and growth at specialized endoplasmic reticulum subdomains.	MCTP1 MCTP2	6.92e-06	2	92	2	33826368
Pubmed	LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity.	LATS1 FOXL2	6.92e-06	2	92	2	20407010
Pubmed	The loss of the CD16 B73.1/Leu11c epitope occurring in some primary immunodeficiency diseases is not associated with the FcgammaRIIIa-48L/R/H polymorphism.	FCGR3A FCGR3B	6.92e-06	2	92	2	20664961
Pubmed	FCGR Genetic Variation in Two Populations From Ecuador Highlands-Extensive Copy-Number Variation, Distinctive Distribution of Functional Polymorphisms, and a Novel, Locally Common, Chimeric FCGR3B/A (CD16B/A) Gene.	FCGR3A FCGR3B	6.92e-06	2	92	2	34108956
Pubmed	Early embryonic lethality in PARP-1 Atm double-mutant mice suggests a functional synergy in cell proliferation during development.	PARP1 ATM	6.92e-06	2	92	2	11238919
Pubmed	Endothelin-converting enzymes degrade α-synuclein and are reduced in dementia with Lewy bodies.	ECE1 ECE2	6.92e-06	2	92	2	28171705
Pubmed	The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.	FCGR3A FCGR3B	6.92e-06	2	92	2	23770975
Pubmed	YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.	YTHDF1 YTHDF2	6.92e-06	2	92	2	34408926
Pubmed	Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis.	FCGR3A FCGR3B	6.92e-06	2	92	2	22290871
Pubmed	Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.	FCGR3A FCGR3B	6.92e-06	2	92	2	20980704
Pubmed	Nucleotide sequence of a new Fc gamma receptor IIIB allele that codes for a neutrophil antigen.	FCGR3A FCGR3B	6.92e-06	2	92	2	11034564
Pubmed	The mechanism underlying redundant functions of the YTHDF proteins.	YTHDF1 YTHDF2	6.92e-06	2	92	2	36694229
Pubmed	Separate promoters from proximal and medial control regions contribute to the natural killer cell-specific transcription of the human FcgammaRIII-A (CD16-A) receptor gene.	FCGR3A FCGR3B	6.92e-06	2	92	2	8940055
Pubmed	The role of ECE1 variants in cognitive ability in old age and Alzheimer's disease risk.	ECE1 ECE2	6.92e-06	2	92	2	22693153
Pubmed	DNA Repair Gene Expression Levels as Indicators of Breast Cancer in the Breast Cancer Family Registry.	MSH2 ATM	6.92e-06	2	92	2	27466510
Pubmed	FCGR3A and FCGR3B copy number variations are risk factors for sarcoidosis.	FCGR3A FCGR3B	6.92e-06	2	92	2	27059607
Pubmed	Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition.	PARP1 ATM	6.92e-06	2	92	2	17459151
Pubmed	The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.	MSH2 LGR5	6.92e-06	2	92	2	34003775
Pubmed	Association of FCGR3A and FCGR3B copy number variations with systemic lupus erythematosus and rheumatoid arthritis in Taiwanese patients.	FCGR3A FCGR3B	6.92e-06	2	92	2	25154742
Pubmed	Ethanol-induced formation of colorectal tumours and precursors in a mouse model of Lynch syndrome.	MSH2 LGR5	6.92e-06	2	92	2	34543445
Pubmed	A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms.	FCGR3A FCGR3B	6.92e-06	2	92	2	2525780
Pubmed	Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy.	PARP1 TERF1	6.92e-06	2	92	2	20137830
Pubmed	Molecular and functional evidence for early divergence of an endothelin-like system during metazoan evolution: analysis of the Cnidarian, hydra.	ECE1 ECE2	6.92e-06	2	92	2	11290299
Pubmed	FcgammaRIII expression on cultured human keratinocytes and upregulation by interferon-gamma.	FCGR3A FCGR3B	6.92e-06	2	92	2	12445195
Pubmed	Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions.	FCGR3A FCGR3B	6.92e-06	2	92	2	2526846
Pubmed	B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.	FCGR3A FCGR3B	6.92e-06	2	92	2	18292508
Pubmed	Major amyloid-β-degrading enzymes, endothelin-converting enzyme-2 and neprilysin, are expressed by distinct populations of GABAergic interneurons in hippocampus and neocortex.	ECE1 ECE2	6.92e-06	2	92	2	27644077
Pubmed	Mutations in LAMA2 and CAPN3 genes associated with genetic and phenotypic heterogeneities within a single consanguineous family involving both congenital and progressive muscular dystrophies.	CAPN3 LAMA2	6.92e-06	2	92	2	20477750
Pubmed	ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.	PARP1 ATM	6.92e-06	2	92	2	20124459
Pubmed	A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse.	CHD7 SNAP25 KIT	9.78e-06	16	92	3	10932191
Pubmed	Defining the membrane proteome of NK cells.	PARP1 FARSA CSE1L KIDINS220 MSH2 RPL14 PLD1 ECE1 MAP2K3 MCTP2 PCM1 XAB2 ITPR2	1.24e-05	1168	92	13	19946888
Pubmed	PARK2 promotes mitochondrial pathway of apoptosis and antimicrotubule drugs chemosensitivity via degradation of phospho-BCL-2.	PARP1 FARSA CSE1L ENAH RPL14 YTHDF2 CA2	1.25e-05	290	92	7	32929329
Pubmed	Characterization of an exchangeable gene trap using pU-17 carrying a stop codon-beta geo cassette.	KIAA1217 PKP4 TTLL4 ENAH PCMTD2 CHD7 HMGCS1 TSPAN9 SMG6	1.28e-05	536	92	9	15840001
Pubmed	Exchangeable gene trap using the Cre/mutated lox system.	KIAA1217 PKP4 TTLL4 ENAH PCMTD2 CHD7 HMGCS1 TSPAN9 SMG6	1.32e-05	538	92	9	10512203
Pubmed	Identifying biological pathways that underlie primordial short stature using network analysis.	PARP1 CSE1L POLR2B ARPC1A MSH2 RPL14 EIF3B THOC2 PCM1 XAB2 DHX8 ITPR2	1.66e-05	1024	92	12	24711643
Pubmed	A multi-factor trafficking site on the spliceosome remodeling enzyme BRR2 recruits C9ORF78 to regulate alternative splicing.	CSE1L ANAPC1 POLR2B ENAH LTN1 SUGP1 HMGCS1 XAB2 DHX8	1.81e-05	560	92	9	35241646
Pubmed	A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.	YTHDF1 KIAA1217 TTLL4 POLR2B ARHGAP12 ARPC1A ENAH TBC1D2B SUGP1 EEF2K GPSM1 YTHDF2	1.90e-05	1038	92	12	26673895
Pubmed	RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease.	YTHDF1 LTN1 MRPL13 DHX57 RPL14 THOC2 YTHDF2 XAB2 LRRFIP2 DHX8	1.96e-05	713	92	10	29802200
Pubmed	Voltage-dependent conformational changes of Kv1.3 channels activate cell proliferation.	DNHD1 PARP1 KIDINS220 MSH2 THOC2 RYR1	1.98e-05	208	92	6	33230847
Pubmed	KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.	MYH11 KIT	2.07e-05	3	92	2	22160378
Pubmed	Fc gamma receptor genes as risk markers for localized aggressive periodontitis in African-Americans.	FCGR3A FCGR3B	2.07e-05	3	92	2	12027254
Pubmed	Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia.	MYH11 KIT	2.07e-05	3	92	2	27650511
Pubmed	YTHDF2 suppresses the plasmablast genetic program and promotes germinal center formation.	YTHDF1 YTHDF2	2.07e-05	3	92	2	35508130
Pubmed	Reelin mobilizes a VAMP7-dependent synaptic vesicle pool and selectively augments spontaneous neurotransmission.	RELN SNAP25	2.07e-05	3	92	2	24210904
Pubmed	Analysis of Fc gamma RIII (CD16) membrane expression and association with CD3 zeta and Fc epsilon RI-gamma by site-directed mutation.	FCGR3A FCGR3B	2.07e-05	3	92	2	1825220
Pubmed	Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease.	FCGR3A FCGR3B	2.07e-05	3	92	2	16133986
Pubmed	Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.	MYH11 CHD7	2.07e-05	3	92	2	29018080
Pubmed	Txk, a member of the non-receptor tyrosine kinase of the Tec family, forms a complex with poly(ADP-ribose) polymerase 1 and elongation factor 1alpha and regulates interferon-gamma gene transcription in Th1 cells.	PARP1 TXK	2.07e-05	3	92	2	17177976
Pubmed	A Unified Model for the Function of YTHDF Proteins in Regulating m6A-Modified mRNA.	YTHDF1 YTHDF2	2.07e-05	3	92	2	32492408
Pubmed	Association between Fcγ receptor IIA, IIIA and IIIB genetic polymorphisms and susceptibility to severe malaria anemia in children in western Kenya.	FCGR3A FCGR3B	2.07e-05	3	92	2	28427365
Pubmed	Different stabilities of the structurally related receptors for IgE and IgG on the cell surface are determined by length of the stalk region in their alpha-chains.	FCGR3A FCGR3B	2.07e-05	3	92	2	16709862
Pubmed	Patterns of low-affinity immunoglobulin receptor polymorphisms in stroke and homozygous sickle cell disease.	FCGR3A FCGR3B	2.07e-05	3	92	2	11835346
Pubmed	FcgammaRIIa, IIIa and IIIb gene polymorphisms in Behçet's disease: do they have any clinical implications?	FCGR3A FCGR3B	2.07e-05	3	92	2	19026120
Pubmed	An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma.	LY75 KIT	2.07e-05	3	92	2	29487009
Pubmed	Immunoglobulin G fc-receptor (FcgammaR) IIA, IIIA, and IIIB polymorphisms related to disease severity in rheumatoid arthritis.	FCGR3A FCGR3B	2.07e-05	3	92	2	12064825
Pubmed	inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.	MYH11 KIT	2.07e-05	3	92	2	23160462
Pubmed	FcgammaRIIA, FcgammaRIIIA and FcgammaRIIIB polymorphisms in Spanish patients with systemic lupus erythematosus.	FCGR3A FCGR3B	2.07e-05	3	92	2	12121275
Pubmed	Infectious complications after chemotherapy and stem cell transplantation in multiple myeloma: implications of Fc gamma receptor and myeloperoxidase promoter polymorphisms.	FCGR3A FCGR3B	2.07e-05	3	92	2	18452102
Pubmed	Fcgamma receptor polymorphisms in relation to periodontitis.	FCGR3A FCGR3B	2.07e-05	3	92	2	12834496
Pubmed	Fc gamma RIIa, IIIa and IIIb polymorphisms in Turkish children susceptible to recurrent infectious diseases.	FCGR3A FCGR3B	2.07e-05	3	92	2	16550341
Pubmed	Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients.	FCGR3A FCGR3B	2.07e-05	3	92	2	14597109
Pubmed	Loss of Wnt4 and Foxl2 leads to female-to-male sex reversal extending to germ cells.	FOXL2 KIT	2.07e-05	3	92	2	17728319
Pubmed	Genetic polymorphism of Fcγ-receptors IIa, IIIa and IIIb in South Indian patients with generalized aggressive periodontitis.	FCGR3A FCGR3B	2.07e-05	3	92	2	22167032
GeneFamily	Multiple C2 and transmembrane domain containing	MCTP1 MCTP2	1.27e-05	2	65	2	826
Coexpression	GSE40666_UNTREATED_VS_IFNA_STIM_STAT4_KO_EFFECTOR_CD8_TCELL_90MIN_DN	DPYD PDE8A BEND5 ENAH PCMTD2 MCTP2 ZNF404	6.64e-06	199	92	7	M9236
ToppCell	pdx\|World / Sample and Cell Type and Tumor Cluster (all cells)	DENND5B NRXN3 MSH2 SNAP25 LGR5 SMG6 ITPR2	1.20e-07	186	92	7	de8e538c8767d41b8a52f5e58ba1affd4e7244c4
ToppCell	pdx-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	DENND5B NRXN3 MSH2 SNAP25 LGR5 SMG6 ITPR2	1.20e-07	186	92	7	0b88a87158a9ca8de3bf40a4ff1687150707a5f0
ToppCell	droplet-Kidney-KIDNEY-1m-Myeloid-nan\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FCGR3A FCGR3B TBC1D2B OAS3 SLAMF7 GPSM1	1.50e-06	171	92	6	d9ad6a3bce3556abd24af1630bf4a99594437c3a
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 MCTP1 KIT ECE2 CA2	2.76e-06	190	92	6	56cc761e50fddfb5366391518b4d8e16589b6b42
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 MCTP1 KIT ECE2 CA2	2.76e-06	190	92	6	25d4b591f75c26e404a34c42f1742d580af6598d
ToppCell	Children_(3_yrs)-Endothelial-capillary_endothelial_cell_(Cap1)-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NRXN3 KIAA1217 PKP4 ECE1 KIT TSPAN9	3.12e-06	194	92	6	68004855b23fe1e31e8452d70effabc78a4a0bd3
ToppCell	healthy_donor-Lymphocytic-ILC-NK_cell\|healthy_donor / Disease condition, Lineage, Cell class and subclass	FCGR3A FCGR3B ATM SLAMF7 MCTP2 TXK	3.51e-06	198	92	6	d7053a898e04478c577381085f615edaad3cdc5b
ToppCell	healthy_donor-Lymphocytic-ILC\|healthy_donor / Disease condition, Lineage, Cell class and subclass	FCGR3A FCGR3B ATM SLAMF7 MCTP2 TXK	3.51e-06	198	92	6	aa33be29e26f1b8facfc894413099083ae3bbb1b
ToppCell	mild-low-quality_cells\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	TENM1 ATM MCTP2 PCM1 SMG6 TXK	3.61e-06	199	92	6	f0b0097df0026496470a80d8cc9375ffd8389b00
ToppCell	Macroglial-Oligodendrocytes\|Macroglial / cells hierarchy compared to all cells using T-Statistic	DPYD NRXN3 PDE8A CAPN3 PLD1 CA2	3.71e-06	200	92	6	4dbac2f2587e87ca5a0622f50439bb5447e93c7f
ToppCell	Macroglial-Oligodendrocytes-OPALIN--\|Macroglial / cells hierarchy compared to all cells using T-Statistic	DPYD NRXN3 PDE8A CAPN3 PLD1 CA2	3.71e-06	200	92	6	26b989e30bbbaf30904ced03f6aae3dea25c732c
ToppCell	Control-Control-Lymphocyte-T/NK-NK\|Control / Disease, condition lineage and cell class	FCGR3A FCGR3B ATM SLAMF7 MCTP2 TXK	3.71e-06	200	92	6	c64c27dbf4df42ca2ad2bd94b50fab87b4050ef3
ToppCell	Macroglial-Oligodendrocytes-OPALIN---\|Macroglial / cells hierarchy compared to all cells using T-Statistic	DPYD NRXN3 PDE8A CAPN3 PLD1 CA2	3.71e-06	200	92	6	1314664c1721e9ecb1e2c3482a039044b0fe50a9
ToppCell	Macroglial-Oligodendrocytes-OPALIN-\|Macroglial / cells hierarchy compared to all cells using T-Statistic	DPYD NRXN3 PDE8A CAPN3 PLD1 CA2	3.71e-06	200	92	6	8b229f095fc113aecfc94b64862a9e0fdcc363ce
ToppCell	Macroglial-Oligodendrocytes-OPALIN----L1-6\|Macroglial / cells hierarchy compared to all cells using T-Statistic	DPYD NRXN3 PDE8A CAPN3 PLD1 CA2	3.71e-06	200	92	6	272909f4354f3ae22e2b2f8f35970e6b0e92cfe2
ToppCell	Macroglial-Oligodendrocytes-OPALIN\|Macroglial / cells hierarchy compared to all cells using T-Statistic	DPYD NRXN3 PDE8A CAPN3 PLD1 CA2	3.71e-06	200	92	6	5f75a9b8bcd49d9bbb1e9ce2de730eaec96369ca
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Lamp5-Lamp5_Lhx6\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	EFCAB6 TENM1 KIT MCTP2 PDE11A	4.48e-06	117	92	5	0602bbad908cb28c5093b74d717da5f2af577943
ToppCell	COVID-19-kidney-Mito-rich_Int\|kidney / Disease (COVID-19 only), tissue and cell type	RELN MYH11 NRXN3 AKR1D1 LAMA2	7.22e-06	129	92	5	57b705106aec7bbfc587de1ccd4f2335fc44dd6f
ToppCell	pdx-Tumor_cells-T9\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	IQCA1L POLR2B ENAH EIF3B MAP2K3	1.23e-05	144	92	5	0b94d978262a826c9254145aa98c6c30240243f9
ToppCell	E16.5-samps-Mesenchymal-Myofibroblast-Migrating_MyoFibroblast\|E16.5-samps / Age Group, Lineage, Cell class and subclass	MYH11 NRXN3 TNN LAMA2 TSHZ1	1.76e-05	155	92	5	1882fa5fd25f77d6e3ac47b613f6fb3c67d8e50c
ToppCell	droplet-Marrow-nan-18m-Lymphocytic-NK_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KIDINS220 FCGR3A FAM3B GPSM1 RYR1	2.11e-05	161	92	5	3f3a2148c8d65e6a06f8d8116a3aa58dda17d618
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Lamp5-Lamp5_Lsp1\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	KIDINS220 EFCAB6 TBC1D2B KIT PDE11A	2.24e-05	163	92	5	bba830a302919c8b33f914a8839877fc21dd28a0
ToppCell	390C-Lymphocytic-NK_cells-NK_cell_C\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	FCGR3A FCGR3B ATM MCTP2 TXK	2.74e-05	170	92	5	81341bf4fe090af70b2091b6b2579ed08d76e22d
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal--glomerular_mesenchymal_cell-Renin-positive_Juxtaglomerular_Granular_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYH11 NRXN3 SNAP25 PLD1 CPED1	2.74e-05	170	92	5	99dd734c0972a40d5381e8e2d96bdaa31f6d06e6
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal--glomerular_mesenchymal_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYH11 NRXN3 SNAP25 PLD1 CPED1	2.74e-05	170	92	5	3a14eeae221b8bb0bd0dadcb8e7a603431240a1e
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYH11 NRXN3 SNAP25 PLD1 CPED1	2.74e-05	170	92	5	cdb6fad277f284c3fd5a6f45672a8edc24715882
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Granulocytic\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	FOXL2 FCGR3A FCGR3B KIT MCTP2	2.98e-05	173	92	5	9eaec30f9a3655b53ece1b66848201a7f85bbdf5
ToppCell	367C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-1\|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)	FCGR3A ATM SLAMF7 MCTP2 TXK	2.98e-05	173	92	5	5d3c917e4d0de3158550a8ab2006ddfa87159ffa
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Cortical_Collecting_Duct_Intercalated_Cell_Type_A\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	NRXN3 TMEM116 LAMA2 KIT ITPR2	3.14e-05	175	92	5	77c16e615c0fb9c83f29d7e0a547be72635fac81
ToppCell	pdx-Tumor_cells-T2\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	RELN FAM3B SNAP25 LGR5 TTC6	3.23e-05	176	92	5	1e21f80cf0e695ffdd63e4a72cf1e3fa41b60341
ToppCell	Control-B_cells\|Control / group, cell type (main and fine annotations)	KLHL6 DENND5B IGHG4 ATM SLAMF7	3.23e-05	176	92	5	9125caa27bf790f6b1b960a86c09b4bcb1b58641
ToppCell	facs-Trachea-24m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l6-17\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MYH11 TTLL4 ARHGAP12 AKR1D1 SNAP25	3.32e-05	177	92	5	8abdf1d970b2f15e17e185f3e612dd5065c88757
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Immune-Myeloid-Granulocytic\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MCTP1 FCGR3A FCGR3B KIT MCTP2	3.41e-05	178	92	5	af9bcee71fb44a6342d4b92bba5b8ddfeeaa24b2
ToppCell	368C-Lymphocytic-ILC-ILC-2\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	MYH11 TPCN2 MCTP1 EEF2K XAB2	3.60e-05	180	92	5	eb5a57604c7f2ad256c300085dbf5069d0ae1ad0
ToppCell	368C-Lymphocytic-ILC\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	MYH11 TPCN2 MCTP1 EEF2K XAB2	3.60e-05	180	92	5	ddba4dc3bbcfe4e4a22400be73bbc62d3ff27d3c
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	RELN NRXN3 ARHGAP12 KIT ECE2	3.79e-05	182	92	5	f2a1784ffcba9b27132e0db21e574cbd8a0a6418
ToppCell	saliva-Severe-critical_progression_d12-22_with-steroid-Myeloid-Granulocytic-Neutrophil-Neu_c1-IL1B\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	MGAM MCTP1 FCGR3B ECE1 MCTP2	3.79e-05	182	92	5	dc32f8f6a3b13918eb8e93c018f5823d86344080
ToppCell	343B-Lymphocytic-NK_cells-NK_cell_D\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	MYH11 FCGR3A ATM SLAMF7 TXK	3.79e-05	182	92	5	c6172aca2475bf0948a78e39f0dae6388504a915
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYH11 LAMA2 CPED1 MCTP2 CA2	3.89e-05	183	92	5	8a799807fbf24456a9811e0c64068187940a2f71
ToppCell	COVID-19-kidney-CD-IC-A\|kidney / Disease (COVID-19 only), tissue and cell type	NRXN3 TMEM116 LAMA2 KIT ITPR2	3.89e-05	183	92	5	5c7597a5b2bf6a481ca2c7e68560179214150fa0
ToppCell	nucseq-Immune-Lymphocytic_B-Lymphocytic_B-Plasma\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	KLHL6 DENND5B IGHG4 ATM SLAMF7	4.10e-05	185	92	5	3b77bc49cd3740acc025e162a36282ac09e12198
ToppCell	pdx-Tumor_cells-T0\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	DENND5B RELN SNAP25 LGR5 ITPR2	4.10e-05	185	92	5	1d874608aa2062024323512f68889219471b2f00
ToppCell	COVID-19_Moderate-NK_activated\|World / disease group, cell group and cell class	MGAM FCGR3A OAS3 MCTP2 TXK	4.21e-05	186	92	5	ff8f32f69516bf785224fa12f8139a95359b0279
ToppCell	Smart-seq2-spleen_(Smart-seq2)-lymphocytic-innate_lymphocytic\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	MGAM FCGR3A ATM MCTP2 TXK	4.21e-05	186	92	5	fc0b488c201a32d829047b58460297df2818b45d
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Neuronal-interneuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RELN NRXN3 MCTP1 CHD7 SNAP25	4.21e-05	186	92	5	d1d01ce46e62944aa9864eda47e8401b5f0d2bdc
ToppCell	CF\|World / Disease state, Lineage and Cell class	MGAM FCGR3B SLAMF7 ECE1 MCTP2	4.31e-05	187	92	5	eec4d4e4a658e3a61c05745167a1a5e3d39bb43e
ToppCell	primary_auditory_cortex_(A1C)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PDE8A CAPN3 CHD7 PLD1 CA2	4.31e-05	187	92	5	b71d0cd91bc98e020757c1d071a13ad48d718bcf
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Neuronal-interneuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RELN NRXN3 MCTP1 CHD7 SNAP25	4.31e-05	187	92	5	1b2fdbfb1ce3f19795dfc4b1da5a94f4b057ec41
ToppCell	Smart-seq2-spleen_(Smart-seq2)-lymphocytic-innate_lymphocytic-mature_NK_T_cell\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	MGAM FCGR3A ATM MCTP2 TXK	4.31e-05	187	92	5	6981b856187a2e689260ecb7d0a1193a374ee9b9
ToppCell	-Unknown-Endothelial-Myofibroblast\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SLC17A5 LATS1 BEND5 TTLL4 CPED1	4.42e-05	188	92	5	6468fa95ad0395395301115286f2d8c0df5d3882
ToppCell	-Unknown-Endothelial\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SLC17A5 LATS1 BEND5 TTLL4 CPED1	4.42e-05	188	92	5	7a81ac5c79c3eb26639b52d2b9fd5e7ef9798fd6
ToppCell	-Unknown\| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SLC17A5 LATS1 BEND5 TTLL4 CPED1	4.42e-05	188	92	5	9cb718bfe1358c6fd842f096e228eb0abb9aefc6
ToppCell	Fetal_29-31_weeks-Immune-natural_killer_cell-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	FCGR3A ATM SLAMF7 MCTP2 TXK	4.42e-05	188	92	5	1082861eb9e00409caa06d8b2a7b8e7f5fac94c9
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIAA1217 TENM1 CPED1 TSPAN9 ECE2	4.42e-05	188	92	5	8de5a07301f9b5984680c873e5a92395b5ed3dd3
ToppCell	Primary_Motor_Cortex_(M1)-Non-neuronal-Macroglial-Oligo\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PDE8A CAPN3 CHD7 PLD1 CA2	4.54e-05	189	92	5	70eea8c94fa56bb15bee8065de47acea156794e9
ToppCell	cellseq-Immune-Hematopoietic-Granulocytic-Neutrophil\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MGAM FCGR3B KIF1B TENM1 MCTP2	4.54e-05	189	92	5	fedab592be1d6520325b8c1b659b0a4dc3f4fe4d
ToppCell	10x_3'_v3-spleen_(10x_3'_v3)\|10x_3'_v3 / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	MGAM FCGR3A FCGR3B SLAMF7 MCTP2	4.54e-05	189	92	5	0fe8901e10c619c93b7788792da1706a32102c6e
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIAA1217 TENM1 CPED1 TSPAN9 ECE2	4.65e-05	190	92	5	d19bc44310c53726e2f5f6a2bd377bbbf1d1983f
ToppCell	PCW_07-8.5-Hematologic_Myeloid-Hem_Myeloid_monocytic-im_immature_monocyte2_(4)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	MCTP1 FCGR3A FGL1 SLAMF7 RYR1	4.65e-05	190	92	5	e5625feb21915d4545cfad2659745ef180efcb1f
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	4.65e-05	190	92	5	3b8d1e66ae68c1eee64095e75195d76d97e24026
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIAA1217 ARHGAP12 TENM1 CPED1 TSPAN9	4.65e-05	190	92	5	3f22c118d552345f731d4d49f0bcb5765d93de3b
ToppCell	COVID-19-kidney-NK\|kidney / Disease (COVID-19 only), tissue and cell type	FCGR3A ATM SLAMF7 MCTP2 TXK	4.65e-05	190	92	5	e3ca3c9fb9e27670a5dd128dd6564ff98a57159e
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIAA1217 TENM1 CPED1 TSPAN9 ECE2	4.65e-05	190	92	5	305fbef734c350cfbf786ca7ff6e07093aab56ea
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	4.65e-05	190	92	5	be2b184a3559da41ba387ae0fdbeb9ae532868a5
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_1\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	4.65e-05	190	92	5	dc655e4782aab274f0c9b6e36a5ce315e3a1a4b9
ToppCell	facs-Pancreas-Endocrine-24m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RELN PKP4 SNAP25 ECE1 GPSM1	4.77e-05	191	92	5	3387b95a3f2445c672d407922fdce3a91eabaef8
ToppCell	PCW_05-06-Hematologic_Myeloid-Hem_Myeloid_monocytic-im_immature_monocyte1_(10)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	KLHL6 MCTP1 FCGR3A FGL1 SLAMF7	4.77e-05	191	92	5	367d300da3925e0a329271b5f19483a37265a878
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	MYH11 NRXN3 LAMA2 ECE1 CPED1	4.77e-05	191	92	5	04c4d454b57e29a8d1dcdeb4678ce71bdc29b77b
ToppCell	Children_(3_yrs)-Immune-natural_killer_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TENM1 ATM SLAMF7 MCTP2 TXK	4.77e-05	191	92	5	9b8b64a36e27a2523b8730c7922fd7ad865a021e
ToppCell	Children_(3_yrs)-Immune-natural_killer_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TENM1 ATM SLAMF7 MCTP2 TXK	4.77e-05	191	92	5	6345c1aa0fd2f9f2154a44f9393bf7c72bb1f44e
ToppCell	B_cells\|World / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	KLHL6 DENND5B IGHG4 CHD7 SLAMF7	4.77e-05	191	92	5	72e3191990973440e4f91427208df360f73e4f41
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	4.89e-05	192	92	5	f6ec683b2133b3095a1fcc06ca8605cf38f774b5
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	4.89e-05	192	92	5	63d1b3efe93e5ff939278ebe40bacb38218ea09b
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	4.89e-05	192	92	5	342842378c20267c5044bdd622515e8b9f895623
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN CHD7 KIT MCTP2 ECE2	4.89e-05	192	92	5	6a252e298f8a454623fa9c1c893a7a45a886d694
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	4.89e-05	192	92	5	bd3fa6c8fcb618db64d11f25cabaf08608957c35
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	4.89e-05	192	92	5	690b3d17c481159bc96b8bc7f6a66b51343ee858
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_1\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	5.01e-05	193	92	5	294cb5b580bb83fe0eb04f112d5507aac35d4d44
ToppCell	NS-critical-d_07-13-Myeloid-Monocyte-derived_Macrophage\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	FCGR3A OAS3 SLAMF7 CPED1 ITPR2	5.01e-05	193	92	5	0dd83b21e164147abfd511a927615c40a28781a2
ToppCell	PCW_13-14-Hematologic_Myeloid-Hem_Myeloid_monocytic-im_monocyte_(14)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	MGAM MCTP1 FCGR3A FCGR3B SLAMF7	5.01e-05	193	92	5	b044fca95f519ff2ceb378afe40a95911931a29e
ToppCell	human_hepatoblastoma-Tumor_cells\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	DENND5B NRXN3 MSH2 TSPAN9 ITPR2	5.01e-05	193	92	5	503a979328c68b096680b71359a26f02fafdff35
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	5.01e-05	193	92	5	3d3c45d5ff6f3396a1990615aae9fe176e799994
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KIAA1217 ARHGAP12 TENM1 CPED1 TSPAN9	5.01e-05	193	92	5	c4b22b62f3cc7bf0ec0eba76e1504c236290bbc9
ToppCell	Children_(3_yrs)-Immune-natural_killer_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TENM1 ATM SLAMF7 MCTP2 TXK	5.01e-05	193	92	5	1cb666375bc4e1b11a146d20896c9b5ae6fd0887
ToppCell	COVID-19-lung-NK/NKT\|COVID-19 / Disease (COVID-19 only), tissue and cell type	FCGR3A ATM SLAMF7 MCTP2 TXK	5.01e-05	193	92	5	c24b44fcc92fff42ebba6f1aff91c7aaea179e56
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	5.14e-05	194	92	5	52aebb0b563e2c2058e7f0554ae870e47692b163
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_1\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	5.14e-05	194	92	5	6ac759828c41ffa974ee82842162caa959351dd1
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_NK-natural_killer_cell\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	FCGR3A ATM SLAMF7 MCTP2 TXK	5.14e-05	194	92	5	a3a81638b55cb5fc08fe83c8b88f68d49b87e6cb
ToppCell	Children_(3_yrs)-Endothelial-capillary_endothelial_cell_(Cap1)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NRXN3 KIAA1217 ECE1 KIT TSPAN9	5.14e-05	194	92	5	71ac69cdf7a08ca3ddfb5b492b14ac56b6cd5e5d
ToppCell	10x5'v1-week_17-19-Myeloid_neutrophil-granulo-neutrophil-neutrophil\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	MGAM FCGR3A FCGR3B HPR CAPN3	5.14e-05	194	92	5	e2d0dfb92356fa7ad7008aa8ac4198e2ac5d2495
ToppCell	droplet-Marrow-nan-3m-Myeloid-granulocytopoietic_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KLHL6 PARP1 SLAMF7 LGR5 PCM1	5.14e-05	194	92	5	8ef0b71fef5b84cfd04973f891215333e7035d1d
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MCTP1 KIAA1217 PKP4 ECE1 KIT	5.14e-05	194	92	5	0b9cd96fa0b616da7cc90e92ff71157e9bba518f
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	5.14e-05	194	92	5	5d0b0d8e96f0e0297a4dba70a05d87081a4eb323
ToppCell	ILEUM-inflamed-(6)_ILC\|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	FCGR3A KIT MCTP2 CA2 TXK	5.14e-05	194	92	5	4d51d49366c34ff1241770b4acc0167a43b3155a
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	5.14e-05	194	92	5	bd06e2b8d8c06cddf2e4f58849b86e09013acae1
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	NRXN3 KIAA1217 ENAH LAMA2 CPED1	5.14e-05	194	92	5	90efdbd7f1c85fd7fd622b10340250b1d8fc1197
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	NRXN3 KIAA1217 ENAH LAMA2 CPED1	5.14e-05	194	92	5	df82cce5ebeb73740b02cf816c6df82253cfd566
ToppCell	systemic_lupus_erythematosus-treated-Lymphocytic_NK-natural_killer_cell-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	FCGR3A ATM SLAMF7 MCTP2 TXK	5.14e-05	194	92	5	0abca32c3547a45cebab0bd69c1f7a0002deaa80
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_NK\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	FCGR3A ATM SLAMF7 MCTP2 TXK	5.26e-05	195	92	5	609732e83ab7fc3ba7dace66f5a17e46557fd6d1
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RELN MYH11 KIT ECE2 CA2	5.26e-05	195	92	5	98ca9f3aa36211dde1e6f7f3817b9418c95e583e
Drug	Bacitracin [1405-87-4]; Down 200; 2.8uM; HL60; HT_HG-U133A	LATS1 CSE1L BEND5 TTLL4 KIF1B SUGP1 LAMA2 PLD1 PCM1 XAB2	6.87e-09	198	91	10	3109_DN
Drug	Fluticasone propionate [80474-14-2]; Down 200; 8uM; MCF7; HT_HG-U133A	DENND5B SUGP1 ATM SNAP25 MAP2K3 KIT PCM1 SMG6	1.07e-06	193	91	8	4129_DN
Drug	magnesium hydroxide	MGAM FCGR3A FCGR3B MRPL13 MSH2 THOC2	4.51e-06	107	91	6	CID000014791
Drug	cortisone 21-acetate	FOXL2 FCGR3A FCGR3B CAPN3 AKR1D1	9.00e-06	70	91	5	CID000002863
Drug	Dicyclomine hydrochloride [67-92-5]; Up 200; 11.6uM; PC3; HT_HG-U133A	SLC17A5 NRXN3 SNAP25 FGL1 MAP2K3 CPED1 ITPR2	1.02e-05	187	91	7	4581_UP
Drug	Diflorasone Diacetate [33564-31-7]; Up 200; 8uM; MCF7; HT_HG-U133A	DENND5B MCTP1 HMGCS1 SNAP25 FGL1 SLAMF7 TSPAN9	1.48e-05	198	91	7	4158_UP
Drug	Pindolol [13523-86-9]; Up 200; 16.2uM; PC3; HT_HG-U133A	MYH11 LATS1 TNN ATM ECE1 SMG6 TXK	1.48e-05	198	91	7	4496_UP
Drug	caffeine	MGAM PARP1 ENPP7 TPCN2 PDE8A LTN1 ATM PLD1 RYR1 CA2 PDE11A	1.49e-05	562	91	11	CID000002519
Drug	S(+)-Terguride [37686-84-3]; Down 200; 11.8uM; HL60; HT_HG-U133A	DENND5B CAPN3 SUGP1 LAMA2 FGL1 MCTP2 ITPR2	1.53e-05	199	91	7	3082_DN
Drug	Sulfadimethoxine [122-11-2]; Up 200; 12.8uM; PC3; HT_HG-U133A	MGAM AKR1D1 SLAMF7 ECE1 TSPAN9 PDE11A ITPR2	1.53e-05	199	91	7	3702_UP
Drug	Iopanoic acid [96-83-3]; Up 200; 7uM; MCF7; HT_HG-U133A	RELN LATS1 PLD1 KIT PCM1 PDE11A ITPR2	1.53e-05	199	91	7	5448_UP
Drug	colchicine; Down 200; 0.1uM; MCF7; HG-U133A	KIDINS220 SUGP1 DHX57 OAS3 HMGCS1 XAB2 ECE2	1.53e-05	199	91	7	644_DN
Drug	Saquinavir mesylate [149845-06-7]; Down 200; 5.2uM; HL60; HT_HG-U133A	DENND5B CSE1L KIDINS220 CAPN3 SUGP1 TSPAN9 PCM1	1.58e-05	200	91	7	6127_DN
Drug	Foliosidine [2520-38-9]; Up 200; 13uM; MCF7; HT_HG-U133A	RELN LATS1 TTLL4 CHD7 ECE1 CPED1 PCM1	1.58e-05	200	91	7	6057_UP
Drug	sertaconazole	SLC17A5 RELN CSE1L EIF3B SNAP25 PCM1 DHX8	2.91e-05	220	91	7	CID000065863
Drug	TCAT	PARP1 DPYD ATM	3.33e-05	16	91	3	CID000013153
Drug	1,4-anthraquinone	MGAM PARP1 CAPN3	4.03e-05	17	91	3	CID000069457
Drug	fluorine atom	MGAM SUGP1 SLAMF7 CA2	4.41e-05	49	91	4	CID005360525
Drug	7-deoxy-6-epi-castanospermine	MGAM CAPN3	4.73e-05	3	91	2	CID000125391
Drug	AC1NUR2V	MGAM CAPN3	4.73e-05	3	91	2	CID005489114
Drug	callyspongynic acid	MGAM CAPN3	4.73e-05	3	91	2	CID000636783
Drug	IPG7F	MGAM CAPN3	4.73e-05	3	91	2	CID003083273
Drug	DPEC	FCGR3A FCGR3B	4.73e-05	3	91	2	CID000129670
Drug	Pradimicin Q	MGAM CAPN3	4.73e-05	3	91	2	CID000073572
Drug	3-nitro-4-(6-aminohexylamido)phenylboronic acid	MGAM CAPN3	4.73e-05	3	91	2	CID000133488
Drug	glycerol-3-phosphocholine	MGAM ENPP7 PDE8A CAPN3 PLD1 PDE11A	6.68e-05	172	91	6	CID000000823
Drug	uranium	MGAM LATS1 POLR2B KIF1B THOC2 XAB2 DHX8	6.87e-05	252	91	7	CID000023989
Drug	AC1NRD8M	MGAM KIDINS220 CAPN3 SNAP25	8.59e-05	58	91	4	CID005289405
Drug	K-Cl	MGAM RELN MYH11 EEF2K FAM3B SNAP25 PLD1 RYR1 CA2 SMG6	8.92e-05	567	91	10	CID000004873
Drug	pay off	MYH11 MSH2 MAP2K3 TXK	9.19e-05	59	91	4	CID000050980
Drug	myrciaphenone B	MGAM CAPN3	9.43e-05	4	91	2	CID000183139
Drug	NSC277293	MGAM CAPN3	9.43e-05	4	91	2	CID000321973
Drug	gamma-glutamyl-2-naphthylamide	MGAM CAPN3	9.43e-05	4	91	2	CID000164706
Drug	atalaphyllidine	MGAM CAPN3	9.43e-05	4	91	2	CID005479542
Drug	Sensodyne	TNN RYR1	9.43e-05	4	91	2	CID000010589
Drug	glycovir	MGAM CAPN3	9.43e-05	4	91	2	CID000060807
Drug	thiochroman-4-one	MGAM CAPN3	9.43e-05	4	91	2	CID000019048
Drug	2-deoxymaltose	MGAM CAPN3	9.43e-05	4	91	2	CID003081508
Drug	AC1L3RZ0	MGAM CAPN3	9.43e-05	4	91	2	CID000145814
Drug	Azaguanine-8 [134-58-7]; Down 200; 26.2uM; HL60; HT_HG-U133A	PARP1 FARSA CSE1L PKP4 MSH2 EIF3B	9.98e-05	185	91	6	1833_DN
Drug	Nocodazole [31430-18-9]; Up 200; 13.2uM; PC3; HT_HG-U133A	HINFP SLC17A5 NRXN3 TTLL4 SUGP1 LGR5	1.16e-04	190	91	6	7145_UP
Drug	C75; Down 200; 10uM; PC3; HT_HG-U133A	PKP4 TBC1D2B LAMA2 ECE1 PCM1 TXK	1.19e-04	191	91	6	6399_DN
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; MCF7; HT_HG-U133A	SLC17A5 TBC1D2B SUGP1 ATM TSPAN9 PCM1	1.22e-04	192	91	6	4743_DN
Drug	Tiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Down 200; 6.4uM; HL60; HG-U133A	MGAM PKP4 ATM MAP2K3 PCM1 DHX8	1.26e-04	193	91	6	1412_DN
Drug	6-Furfurylaminopurine [525-79-1]; Up 200; 18.6uM; PC3; HT_HG-U133A	NRXN3 TTLL4 TENM1 SUGP1 ATM ECE1	1.26e-04	193	91	6	4477_UP
Drug	Hydroxytacrine maleate (R,S) [118909-22-1]; Down 200; 12.2uM; HL60; HT_HG-U133A	KIDINS220 PKP4 ATM FGL1 MCTP2 PCM1	1.29e-04	194	91	6	2430_DN
Drug	STOCK1N-35215; Down 200; 10uM; PC3; HT_HG-U133A	DENND5B ECE1 CPED1 PCM1 RYR1 CA2	1.29e-04	194	91	6	6380_DN
Drug	Bepridil hydrochloride [74764-40-2]; Up 200; 10uM; HL60; HT_HG-U133A	PDE8A SUGP1 LAMA2 DHX57 PLD1 MCTP2	1.29e-04	194	91	6	1274_UP
Drug	Haloperidol [52-86-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A	LATS1 HMGCS1 FGL1 MAP2K3 MCTP2 TSPAN9	1.33e-04	195	91	6	1539_UP
Drug	Piperidolate hydrochloride [129-77-1]; Down 200; 11.2uM; HL60; HT_HG-U133A	PKP4 CAPN3 DHX57 ATM PLD1 PCM1	1.33e-04	195	91	6	6129_DN
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A	ATM FGL1 ECE1 XAB2 SMG6 ITPR2	1.33e-04	195	91	6	3893_DN
Drug	Ascorbic acid [50-81-7]; Up 200; 22.4uM; MCF7; HT_HG-U133A	TBC1D2B SUGP1 OAS3 PLD1 FGL1 TSPAN9	1.37e-04	196	91	6	5407_UP
Drug	CP-320650-01 [172079-28-6]; Down 200; 1uM; PC3; HT_HG-U133A	LATS1 NRXN3 PKP4 ECE1 CPED1 TSPAN9	1.37e-04	196	91	6	4560_DN
Drug	Enoxacin [74011-58-8]; Up 200; 12.4uM; MCF7; HT_HG-U133A	DENND5B PLD1 SLAMF7 KIT PCM1 ITPR2	1.37e-04	196	91	6	5251_UP
Drug	Scoulerine [6451-73-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A	LATS1 MCTP1 SUGP1 LAMA2 ECE1 CPED1	1.37e-04	196	91	6	5536_UP
Drug	Mifepristone [84371-65-3]; Down 200; 9.4uM; PC3; HT_HG-U133A	CSE1L TTLL4 SUGP1 ATM ECE1 TSPAN9	1.37e-04	196	91	6	5827_DN
Drug	Canavanine sulfate monohydrate (L,+) [206996-57-8]; Down 200; 13.6uM; MCF7; HT_HG-U133A	ARHGAP12 PCMTD2 MSH2 ATM TSPAN9 CA2	1.37e-04	196	91	6	4782_DN
Drug	Nortriptyline hydrochloride [894-71-3]; Up 200; 13.4uM; PC3; HT_HG-U133A	CSE1L CHD7 HMGCS1 LGR5 TSPAN9 ITPR2	1.37e-04	196	91	6	7300_UP
Drug	Thyroxine (L) [51-48-9]; Up 200; 5.2uM; PC3; HT_HG-U133A	NRXN3 AKR1D1 LAMA2 SLAMF7 PDE11A ITPR2	1.41e-04	197	91	6	4069_UP
Drug	Cinnarizine [298-57-7]; Up 200; 10.8uM; MCF7; HT_HG-U133A	CSE1L KIDINS220 MCTP1 ATM ECE1 PCM1	1.41e-04	197	91	6	7174_UP
Drug	Dihydroergotamine tartrate [5989-77-5]; Up 200; 3uM; PC3; HT_HG-U133A	MYH11 NRXN3 TTLL4 LAMA2 ECE1 TXK	1.41e-04	197	91	6	4502_UP
Drug	Piperacillin sodium salt [59703-84-3]; Down 200; 7.4uM; PC3; HT_HG-U133A	NRXN3 BEND5 SUGP1 CPED1 SMG6 ITPR2	1.41e-04	197	91	6	3763_DN
Drug	Streptomycin sulfate [3810-74-0]; Down 200; 2.8uM; HL60; HG-U133A	HINFP MGAM PCMTD2 SNAP25 MAP2K3 PCM1	1.41e-04	197	91	6	1578_DN
Drug	Ipratropium bromide [22254-24-6]; Up 200; 9.8uM; PC3; HT_HG-U133A	SLC17A5 NRXN3 SUGP1 DHX57 CHD7 MCTP2	1.41e-04	197	91	6	5823_UP
Drug	Nalbuphine hydrochloride [23277-43-2]; Up 200; 10.2uM; MCF7; HT_HG-U133A	RELN CSE1L HMGCS1 FGL1 TSPAN9 PCM1	1.41e-04	197	91	6	7177_UP
Drug	Terbutaline hemisulfate [23031-32-5]; Down 200; 7.2uM; MCF7; HT_HG-U133A	PKP4 TTLL4 SUGP1 DHX57 PCM1 LRRFIP2	1.41e-04	197	91	6	6240_DN
Drug	Dihydroergocristine mesylate [24730-10-7]; Down 200; 5.6uM; PC3; HT_HG-U133A	SLC17A5 PKP4 SUGP1 OAS3 TSPAN9 LRRFIP2	1.45e-04	198	91	6	7275_DN
Drug	Betonicine [515-25-3]; Up 200; 25.2uM; PC3; HT_HG-U133A	LATS1 PKP4 SUGP1 CPED1 PCM1 ITPR2	1.45e-04	198	91	6	4301_UP
Drug	Antipyrine [60-80-0]; Up 200; 21.2uM; PC3; HT_HG-U133A	BEND5 PKP4 TENM1 PLD1 KIT MCTP2	1.45e-04	198	91	6	4251_UP
Drug	Fluspirilen [1841-19-6]; Down 200; 8.4uM; MCF7; HT_HG-U133A	CSE1L MCTP1 SUGP1 ZNF721 TSPAN9 CA2	1.45e-04	198	91	6	6463_DN
Drug	Trimethadione [127-48-0]; Up 200; 28uM; HL60; HT_HG-U133A	RELN PKP4 LAMA2 FGL1 TSPAN9 RYR1	1.45e-04	198	91	6	2486_UP
Drug	Ceforanide [60925-61-3]; Up 200; 7.6uM; PC3; HT_HG-U133A	BEND5 PKP4 TENM1 SUGP1 LAMA2 MCTP2	1.45e-04	198	91	6	6751_UP
Drug	PF-00562151-00 [351320-12-2]; Up 200; 10uM; PC3; HT_HG-U133A	MCTP1 PDE8A TTLL4 ARHGAP12 OAS3 TSPAN9	1.45e-04	198	91	6	6907_UP
Drug	1,1-dimethylbiguanide hydrochloride; Down 200; 10uM; MCF7; HG-U133A	HINFP KIDINS220 CAPN3 OAS3 PCM1 XAB2	1.49e-04	199	91	6	61_DN
Drug	Methylhydantoin-5-(D) [55147-68-7]; Down 200; 35uM; PC3; HT_HG-U133A	SUGP1 SLAMF7 LGR5 CPED1 PCM1 TXK	1.49e-04	199	91	6	3994_DN
Drug	Nomifensine maleate [32795-47-4]; Up 200; 11.2uM; PC3; HT_HG-U133A	NRXN3 SUGP1 PLD1 CPED1 TSPAN9 SMG6	1.49e-04	199	91	6	2062_UP
Drug	Benzathine benzylpenicillin [5928-84-7]; Down 200; 4.2uM; MCF7; HT_HG-U133A	KIDINS220 TTLL4 SUGP1 ATM PCM1 SMG6	1.49e-04	199	91	6	4140_DN
Drug	PHA-00745360 [351320-33-7]; Down 200; 1uM; PC3; HT_HG-U133A	LATS1 NRXN3 TENM1 SUGP1 ECE1 CPED1	1.49e-04	199	91	6	4562_DN
Drug	Piperine [94-62-2]; Up 200; 14uM; PC3; HT_HG-U133A	NRXN3 PKP4 AKR1D1 SUGP1 LAMA2 SLAMF7	1.49e-04	199	91	6	4247_UP
Drug	Ribavirin [36791-04-5]; Up 200; 16.4uM; MCF7; HT_HG-U133A	KIDINS220 EFCAB6 LAMA2 ATM SNAP25 PDE11A	1.49e-04	199	91	6	6521_UP
Drug	Tubocurarine chloride pentahydrate (+) [6989-98-6]; Up 200; 5.2uM; MCF7; HT_HG-U133A	RELN TTLL4 CPED1 TSPAN9 PCM1 ITPR2	1.49e-04	199	91	6	5449_UP
Drug	Canavanine sulfate monohydrate (L,+) [206996-57-8]; Up 200; 13.6uM; PC3; HT_HG-U133A	KIDINS220 TTLL4 CAPN3 LAMA2 FGL1 ITPR2	1.49e-04	199	91	6	4197_UP
Drug	Levodopa [59-92-7]; Up 200; 20.2uM; PC3; HT_HG-U133A	LATS1 TBC1D2B TENM1 PLD1 FGL1 SMG6	1.49e-04	199	91	6	4571_UP
Drug	telomestatin	MSH2 MAP2K3 SMG6	1.50e-04	26	91	3	CID000443590
Drug	Schiff's reagent	LATS1 SLAMF7 ECE1	1.50e-04	26	91	3	CID000010484
Drug	Epirizole [18694-40-1]; Down 200; 17uM; MCF7; HT_HG-U133A	SLC17A5 KIDINS220 PKP4 TTLL4 SUGP1 MAP2K3	1.53e-04	200	91	6	1681_DN
Drug	S-acetylthioacetic acid	HPR ECE1	1.57e-04	5	91	2	CID000014485
Drug	tetrachlorophthalimide	MGAM CAPN3	1.57e-04	5	91	2	CID000074077
Drug	D-gluco-octenitol	MGAM CAPN3	1.57e-04	5	91	2	CID006438548
Drug	Bn-4	FCGR3A FCGR3B	1.57e-04	5	91	2	CID006452014
Drug	(-)-Lentiginosine	MGAM CAPN3	1.57e-04	5	91	2	CID000130407
Drug	beta-D-glucopyranosyl azide	MGAM CAPN3	1.57e-04	5	91	2	CID000152302
Drug	pulmatin	MGAM CAPN3	1.57e-04	5	91	2	CID000442731
Drug	Ro 22-0654	MGAM CAPN3	1.57e-04	5	91	2	CID000133753
Drug	caged InsP3	CLCA4 RYR1 CA2	2.09e-04	29	91	3	CID000122248
Drug	magnesium	MGAM ENPP7 FARSA MYH11 CSE1L PDE8A POLR2B ARPC1A LAMA2 MRPL13 MSH2 SNAP25 PLD1 RYR1 CA2	2.31e-04	1325	91	15	CID000000888
Drug	Nsc1222	MGAM HPR CAPN3	2.32e-04	30	91	3	CID000219660
Drug	TAN-1030A	FCGR3A FCGR3B	2.35e-04	6	91	2	CID009576886
Drug	bismaleimide	FCGR3A FCGR3B	2.35e-04	6	91	2	CID000083648
Drug	AC1OCFTL	MGAM CAPN3	2.35e-04	6	91	2	CID006918743
Disease	level of low affinity immunoglobulin gamma Fc region receptor III-A in blood serum	FCGR3A FCGR3B	9.41e-06	2	91	2	OBA_2040305
Disease	low affinity immunoglobulin gamma Fc region receptor II-a measurement	FCGR3A FCGR3B SLAMF7	1.87e-05	17	91	3	EFO_0021969
Disease	Lupus Vasculitis, Central Nervous System	FCGR3A FCGR3B	2.82e-05	3	91	2	C0752332
Disease	Lupus Meningoencephalitis	FCGR3A FCGR3B	2.82e-05	3	91	2	C0752334
Disease	Neuropsychiatric Systemic Lupus Erythematosus	FCGR3A FCGR3B	2.82e-05	3	91	2	C0752335
Disease	tea consumption measurement	MGAM NRXN3 SUGP1 LAMA2 PCMTD2	5.08e-05	129	91	5	EFO_0010091
Disease	Acute myelomonocytic leukemia	MYH11 KIT	9.35e-05	5	91	2	C0023479
Disease	Autism Spectrum Disorders	DPYD RELN NRXN3 CA2	1.42e-04	85	91	4	C1510586
Disease	low affinity immunoglobulin gamma Fc region receptor II-a/b measurement	FCGR3A FCGR3B	1.96e-04	7	91	2	EFO_0008211
Disease	permanent dental caries	MGAM PDE11A	1.96e-04	7	91	2	EFO_0600096
Disease	Adenocarcinoma of large intestine	EEF2K MSH2 ATM KIT	2.26e-04	96	91	4	C1319315
Disease	renal cell carcinoma	ATM PLD1 ITPR2	2.99e-04	42	91	3	EFO_0000681
Disease	arthritis (is_implicated_in)	PARP1 FCGR3A	3.34e-04	9	91	2	DOID:848 (is_implicated_in)
Disease	plexin-B2 measurement	FCGR3A FCGR3B	3.34e-04	9	91	2	EFO_0021867
Disease	response to hydrochlorothiazide, diastolic blood pressure change measurement	ENPP7 TTC6	4.17e-04	10	91	2	EFO_0005202, EFO_0006945
Disease	telomere length	PARP1 NRXN3 MCTP1 ATM TERF1 TSPAN9	4.25e-04	313	91	6	EFO_0004505
Disease	aspartate aminotransferase measurement	SLC17A5 FCGR3A FCGR3B HPR SUGP1 LY75 TSPAN9 TTC6 SMG6 TXK	4.74e-04	904	91	10	EFO_0004736
Disease	Congenital muscular dystrophy	LAMA2 RYR1	6.08e-04	12	91	2	cv:C0699743
Disease	basophil count	FCGR3A FCGR3B CAPN3 ECE1 KIT YTHDF2 RYR1	7.47e-04	483	91	7	EFO_0005090
Disease	low affinity immunoglobulin gamma Fc region receptor III-B measurement	FCGR3A FCGR3B	8.36e-04	14	91	2	EFO_0008212
Disease	basophil percentage of leukocytes	FCGR3A FCGR3B CHD7 ECE1 RYR1	9.51e-04	243	91	5	EFO_0007992
Disease	hemoglobin A1 measurement	MGAM FARSA PLD1 GPSM1 MAP2K3 YTHDF2 SMG6	1.15e-03	520	91	7	EFO_0007629
Disease	Conventional (Clear Cell) Renal Cell Carcinoma	DNHD1 RPL14 ATM RYR1	1.16e-03	148	91	4	C0279702
Disease	muscular dystrophy (is_implicated_in)	CAPN3 LAMA2	1.24e-03	17	91	2	DOID:9884 (is_implicated_in)
Disease	cancer (implicated_via_orthology)	LATS1 MSH2 ATM GPSM1 KIT	1.47e-03	268	91	5	DOID:162 (implicated_via_orthology)
Disease	laryngeal squamous cell carcinoma (is_marker_for)	FOXL2 MSH2	1.55e-03	19	91	2	DOID:2876 (is_marker_for)
Disease	Colorectal cancer, hereditary nonpolyposis, type 1	MSH2 ATM	1.55e-03	19	91	2	C2936783
Disease	Colorectal Neoplasms	PARP1 DPYD FOXL2 MSH2 LGR5	1.69e-03	277	91	5	C0009404
Disease	disease of metabolism (implicated_via_orthology)	YTHDF1 YTHDF2	1.90e-03	21	91	2	DOID:0014667 (implicated_via_orthology)
Disease	Immunologic Deficiency Syndromes	CHD7 ATM	2.28e-03	23	91	2	C0021051
Disease	Malignant neoplasm of stomach	DPYD MRPL13 MSH2 ATM CA2	2.40e-03	300	91	5	C0024623
Disease	peptic ulcer disease, Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement, gastroesophageal reflux disease	DPYD TERF1	2.48e-03	24	91	2	EFO_0003948, EFO_0009923, MONDO_0004247
Disease	unipolar depression, neuroticism measurement	KIAA1217 TSPAN9	2.48e-03	24	91	2	EFO_0003761, EFO_0007660
Disease	low affinity immunoglobulin gamma Fc region receptor II-b measurement	FCGR3A FCGR3B	2.69e-03	25	91	2	EFO_0021970
Disease	Hereditary Nonpolyposis Colorectal Neoplasms	MSH2 ATM	2.91e-03	26	91	2	C0009405
Disease	sensory perception of bitter taste	MGAM MCTP2	2.91e-03	26	91	2	GO_0050913

Protein segments in the cluster

Peptide	Gene	Start	Entry
DLRSIYKKDGWNQNH	PKP4	996	Q99569
YKKDGWNQNHFITPV	PKP4	1001	Q99569
KWHQLQVTQGDSKYT	BEND5	311	Q7L4P6
ANYGKARSWYLKAQH	SMG6	746	Q86US8
NVVDCKLHWQKNGDY	EIF3B	511	P55884
EWQKVHGTKFYHNVN	CPED1	796	A4D0V7
THFWNDENGNKYRKA	AACS	496	Q86V21
ENGKWLYHKSNLCAT	AKR1D1	136	P51857
ESVNDGKQASWYIHK	DPYD	491	Q12882
AKTLSQAQCGQYHKW	DNHD1	3396	Q96M86
YQWDGNLKPQAKSAH	DNHD1	3521	Q96M86
LNHYKGDENIKSFIW	CHD7	1651	Q9P2D1
EVHIYKKNGSQWVKA	ARPC1A	31	Q92747
YCKKIHAQWQKEGND	HMGCS1	236	Q01581
KLYEEKTGNAWHSKN	PARP1	616	P09874
QYWKAKQAKQGNHTE	ITPR2	71	Q14571
SQNKFWKYGKHSVPQ	LTN1	256	O94822
AWIVYNKPKHAELAN	ANAPC1	1156	Q9H1A4
DNKTALYWAVEKGNA	KIDINS220	301	Q9ULH0
ISGGKETQHDVWKYN	KLHL6	381	Q8WZ60
LTHTVYKNLNPEWNK	MCTP1	661	Q6DN14
HTVYKNLNPEWNKVF	MCTP2	546	Q6DN12
SQTKLQEKYNSWHHG	KIT	251	P10721
NVNDTLNGWYKNGKH	LATS1	1056	O95835
NIGNVYHAKGKQLSW	GPSM1	151	Q86YR5
YHAKGKQLSWNAANA	GPSM1	156	Q86YR5
WGQSDNFKLTDHLKY	HPR	226	P00739
AVEVQDLKNGATHYW	KIF1B	826	O60333
DAVQHWGKQYDIHNL	MGAM	571	O43451
NAYKAWLRKHGEEQQ	ECE2	721	P0DPD6
HNSYNGKETKNRWKN	PCM1	941	Q15154
FKENAYKDLAWKHGN	PCMTD2	46	Q9NV79
VSKGEYDWNIKNHRD	PDE11A	791	Q9HCR9
DLMQHLDNNFKYWKG	PDE8A	801	O60658
YEKNKKGWQNSIRHN	FOXL2	91	P58012
KATQKKANDGEWYHV	NRXN3	531	Q9Y4C0
YAGQKLNDNEWHTVR	NRXN3	766	Q9Y4C0
AAKENGSRWIQYKGH	LY75	1531	O60449
KKFTDYHQWNSAGVG	GOLGA6L7	16	A0A1B0GV03
VVSNQNHNDGKWKSF	LAMA2	2411	P24043
KINHSDAKNNRYSGW	FAM3B	206	P58499
QQKEYSLHSFDRKWG	LRRFIP2	56	Q9Y608
SVQLQYSLNNGKDWH	RELN	1681	P78509
NEKWLKHVDDQGRQY	ARHGAP12	361	Q8IWW6
HSDSKQGKYLNWDAV	ATM	46	Q13315
QAHQYLVTKAKNRWS	EFCAB6	836	Q5THR3
NFVQKHGEYWLGNKN	FGL1	146	Q08830
RYDWQAKSVHAENGK	DHX57	506	Q6P158
KSKVLAHYPQNIEWN	DENND5B	56	Q6ZUT9
WKNTALHKVTYLQNG	FCGR3B	131	O75015
NWYVDGVEVHNAKTK	IGHG4	156	P01861
LHAQQWKGASNYVAK	EEF2K	156	O00418
KGLKYNQATQTFHQW	ENAH	66	Q8N8S7
AYQNWVKKNGAEHSL	ECE1	681	P42892
GIAHNYKNETEWRAN	ENPP7	161	Q6UWV6
WKNTALHKVTYLQNG	FCGR3A	131	P08637
YHTKLKQWGLQALQS	HINFP	91	Q9BQA5
AWQKIFKHYDTDQSG	CAPN3	726	P20807
KVHHNQTGKKYQWDA	SLC17A5	91	Q9NRA2
EQLAENYHNTWGRKK	RYR1	2876	P21817
NYHNTWGRKKKQELE	RYR1	2881	P21817
RAGNKASKENDWYLA	MSH2	106	P43246
LAVYNSWKNNKFSNP	DHX8	1046	Q14562
ENAYKISNQWNKGDN	LGR5	486	O75473
KHWYRQVAAQNKGKG	OAS3	606	Q9Y6K5
NQKGYNVKSDVWSLG	MAP2K3	241	P46734
SKAGKSNYQLWHELC	XAB2	211	Q9HCS7
SYHQGLKKWVEVGNS	FARSA	421	Q9Y285
IQENALAKWYVNAKG	PLD1	346	Q13393
WHKFSQGQAAVTIQK	IQCA1L	201	A6NCM1
YSLATGNWGDQKKAH	POLR2B	446	P30876
KWEEKRQNLDHYNGK	KIAA1217	971	Q5T5P2
NGLLQKAYNKASGWT	TENM1	2231	Q9UKZ4
KSSDAYKKAWGNNQD	SNAP25	96	P60880
YKKAWGNNQDGVVAS	SNAP25	101	P60880
VHWNTKYGDFGKAVQ	CA2	121	P00918
KVGTWAYNLQAKANP	CLCA4	561	Q14CN2
AGKVDYNASAWLTKN	MYH11	581	P35749
LWEKAVQQHQHGYDS	SUGP1	471	Q8IWZ8
YAKNPSVNWKHKDAA	CSE1L	416	P55060
QWKNETYNSHPLLVK	THOC2	526	Q8NI27
LQAQGKFQKAWNHFT	TTC6	291	Q86TZ1
YTVHVWAQKGNQESK	TNN	861	Q9UQP3
HSAHQKYVRQAWQKA	RPL14	66	P50914
GKDFGWYTDLNQHKK	ZNF721	131	Q8TF20
VYGWTQHKFHQLKQE	TMEM116	191	Q8NCL8
GNWSKILLHYKFNNR	TERF1	401	P54274
IYTWKALGQAANESH	SLAMF7	161	Q9NQ25
AFSGNKWEQKVYSSH	MRPL13	66	Q9BYD1
NAYHQETWKRNKTFN	ZNF404	66	Q494X3
KKNDSGQWYVAERHA	TXK	206	P42681
NILTTQWEQKYHGNK	TTLL4	1046	Q14679
QWEQKYHGNKLKGVD	TTLL4	1051	Q14679
NFYSLKQWGNELKNS	TBC1D2B	216	Q9UPU7
GYDWHQAALAKTLQQ	TSHZ1	196	Q6ZSZ6
SVKGYLFGWAHFQKN	TPCN2	141	Q8NHX9
YHTENNVGLKNAWNI	TSPAN9	126	O75954
NNYNPKDFDWNLKHG	YTHDF2	396	Q9Y5A9
LKAAHSYNPKEFEWN	YTHDF1	371	Q9BYJ9